Pacira BioSciences, Inc. (PCRX) Stock Analysis
A live, multi-source view of Pacira BioSciences, Inc. (PCRX): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019.
Sector: Healthcare · Industry: Drug Manufacturers - Specialty & Generic · United States · 825 employees · pacira.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Pacira BioSciences, Inc. (PCRX) had a market capitalization of $1.05B, a trailing P/E of 75.3 (forward 7.6) and a beta of 0.27; the shares traded in a 52-week range of $18.80 – $27.66 (-0.5% over the year).
- Market cap
- $1.05B
- Enterprise value
- $1.21B
- Trailing P/E
- 75.3
- Forward P/E
- 7.6
- PEG ratio
- 11.21
- Price / book
- 1.56
- EPS (trailing)
- $0.35
- EPS (forward)
- $3.45
- Payout ratio
- 0.0%
- 52-week range
- $18.80 – $27.66
- 52-week change
- -0.5%
- Beta
- 0.27
- Average volume
- 563,943
- Shares outstanding
- 39.9M
- Short % of float
- 26.32%
- Profit margin
- 2.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-11
In RapidTradeView’s 2026-09-11 scan of the US universe, Pacira BioSciences, Inc. (PCRX) last closed at $25.16 (the last completed close before that scan).
Technicals at the scan: RSI 47 (neutral territory), price +0.0% versus its 20-day average, 20-day versus 50-day average spread -1.2%, MACD histogram 0.02.
Sentiment inputs: 100% of recent Finnhub-scored headlines read bullish; StockTwits 100% bullish; analyst consensus score 59/100.
Next scheduled company event: in 55 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of PCRX; corporate insiders filed 0 buys and 1 sell (1 filer, latest disclosure 2026-08-18). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: Jonathan Slonin (0B/1S). Who is trading what
RapidTradeView pick record
PCRX has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Pacira BioSciences, Inc. (PCRX) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell PCRX.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.